DATHYRCA guidelines - Dahanca
DATHYRCA guidelines - Dahanca
DATHYRCA guidelines - Dahanca
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
cancers. Cancer 1985;55:2062-71.<br />
Guidelines - Thyreoideacancer – revideret oktober 2005<br />
139. Farahati J, Reiners C, Stuschke M, Muller SP, Stuben G, Sauerwein W et al. Differentiated thyroid<br />
cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage<br />
pT4). Cancer 1996;77:172-80.<br />
140. Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the<br />
thyroid. J.Clin.Endocrinol.Metab 1983;57:124-8.<br />
141. Rasmusson B, Hansen HS. Treatment of medullary carcinoma of the thyroid. Value of calcitonin as<br />
tumour marker. Acta Radiol.Oncol.Radiat.Phys.Biol. 1979;18:521-34.<br />
142. Tennvall, J., Lundell, G., Wahlberg, P., and Wallin, G. Combined Doxorubicin, hyperfrationated radiotherapy<br />
and surgery in anaplastic thyroid carcinoma. Report on three consecutive protocols. 23. 2000.<br />
Aarhus, Denmark.<br />
Ref Type: Conference Proceeding<br />
143. Merrick Y, Hansen HS. Thyroid cancer in children and adolescents in Denmark. Eur.J.Surg.Oncol.<br />
1989;15:49-53.<br />
144. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. Diagnostic value of a single serum thyroglobulin<br />
determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated<br />
thyroid cancer. Clin.Endocrinol.(Oxf) 1985;23:405-11.<br />
145. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI et al. A comparison of<br />
recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or<br />
cancer. J.Clin.Endocrinol.Metab 1999;84:3877-85.<br />
146. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B et al. Follow-up of low-risk patients<br />
with differentiated thyroid carcinoma: a European perspective. Eur.J.Endocrinol. 2004;150:105-12.<br />
147. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L et al. A consensus<br />
report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary<br />
thyroid carcinoma. J.Clin.Endocrinol.Metab 2003;88:1433-41.<br />
148. Tolaney, S and Ladenson, P. W. Use of recombinant TSH in thyroid disease: An evidence-based review.<br />
Thyroid International 5, 1-17. 2003. Darmstadt, Germany, Merck KGaA.<br />
Ref Type: Magazine Article<br />
149. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J.Surg.<br />
1981;5:39-47.<br />
150. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS et al. Thyrotropin suppression and<br />
disease progression in patients with differentiated thyroid cancer: results from the National Thyroid<br />
Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-44.<br />
151. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA et al. Point mutation within the<br />
tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related<br />
sporadic tumours [published erratum appears in Hum Mol Genet 1994 Apr;3(4):686]. Hum.Mol.Genet.<br />
1994;3:237-41.<br />
152. Donis KH, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. Mutations in the RET protooncogene<br />
are associated with MEN 2A and FMTC. Hum.Mol.Genet. 1993;2:851-6.<br />
153. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. A mutation in the RET<br />
proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid<br />
58
Change language